Search Our Site

News tagged with:

"treatment"

FDA approves first biosimilar for the treatment of certain breast and stomach cancers

The U.S. Food and Drug Administration today approved Ogivri (trastuzumab-dkst) as a biosimilar to Herceptin (trastuzumab) for the treatment of patients with breast or metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma) whose tumors overexpress the HER2 gene (HER2+). Ogivri is the first biosimilar approved in the U.S. for the treatment of breast cancer or... Read More »

Read More →

The U.S. Food and Drug Administration today approved Ogivri (trastuzumab-dkst) as a biosimilar to Herceptin (trastuzumab) for the treatment of patients with breast or metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma) whose tumors overexpress the HER2 gene (HER2+). Ogivri is the first biosimilar approved in the U.S. for the treatment of breast cancer or… Read More »

[...]

Read More

Gene Therapy May Fight Brain Cancer’s Return

A new form of gene therapy shows promise in battling recurrent brain cancer. The phase 1 clinical trial included 56 patients with recurrent high-grade glioma brain cancer. Three years after the gene therapy treatment, more than a quarter of the patients were still alive. Median survival for patients was 14.4 months, compared with eight months... Read More »

Read More →

A new form of gene therapy shows promise in battling recurrent brain cancer. The phase 1 clinical trial included 56 patients with recurrent high-grade glioma brain cancer. Three years after the gene therapy treatment, more than a quarter of the patients were still alive. Median survival for patients was 14.4 months, compared with eight months… Read More »

[...]

Read More

Read the Fine Print on the $475,000 Price of a Cancer Breakthrough

Novartis could have priced Kymriah much higher, and it’s being unusually flexible. Kicking it off, Gilead Sciences Inc. bought Kite Pharma Inc., a pioneer in “CAR-T” cell therapy, which uses a patient’s immune cells to potentially eradicate blood cancers with just one treatment. And on Wednesday, Novartis AG’s entry in this field, Kymriah, became the first such... Read More »

Read More →

Novartis could have priced Kymriah much higher, and it’s being unusually flexible. Kicking it off, Gilead Sciences Inc. bought Kite Pharma Inc., a pioneer in “CAR-T” cell therapy, which uses a patient’s immune cells to potentially eradicate blood cancers with just one treatment. And on Wednesday, Novartis AG’s entry in this field, Kymriah, became the first such… Read More »

[...]

Read More

Meds by Monthly Injection Might Revolutionize HIV Care

Getting a shot of medication to control HIV every month or two instead of having to take pills every day could transform the way the virus is kept at bay New research suggests that injectable, long-acting antiretroviral therapy for HIV is as safe and effective as oral medications. The injection — given every four or... Read More »

Read More →

Getting a shot of medication to control HIV every month or two instead of having to take pills every day could transform the way the virus is kept at bay New research suggests that injectable, long-acting antiretroviral therapy for HIV is as safe and effective as oral medications. The injection — given every four or… Read More »

[...]

Read More

Tumor Test Helps Identify Which Breast Cancers Don’t Require Extra Treatment

For years, doctors have focused on detecting breast cancer at the earliest possible moment after a tumor develops so treatment can start right away. But more and more studies are showing many small, early tumors don’t present a danger. So, when is it safe to remove a tumor but skip additional treatments like tamoxifen, chemotherapy... Read More »

Read More →

For years, doctors have focused on detecting breast cancer at the earliest possible moment after a tumor develops so treatment can start right away. But more and more studies are showing many small, early tumors don’t present a danger. So, when is it safe to remove a tumor but skip additional treatments like tamoxifen, chemotherapy… Read More »

[...]

Read More

CAR T-cell Therapy May Thwart Multiple Myeloma

Genetically tuning a person’s own immune cells to target cancer appears to provide long-lasting protection against a blood cancer called multiple myeloma, an early trial from China shows. The treatment, called CAR T-cell therapy, caused 33 out of 35 patients with recurring multiple myeloma to either enter full remission or experience a significant reduction in... Read More »

Read More →

Genetically tuning a person’s own immune cells to target cancer appears to provide long-lasting protection against a blood cancer called multiple myeloma, an early trial from China shows. The treatment, called CAR T-cell therapy, caused 33 out of 35 patients with recurring multiple myeloma to either enter full remission or experience a significant reduction in… Read More »

[...]

Read More

A New Cancer Drug Helped Almost Everyone Who Took It. Almost. Here’s What It Teaches Us

Derek Laurie was working as a tow truck driver, living in a suburb outside Rochester, New York, and supporting two small children. It was tough work. He climbed under wrecked vehicles, or swam into ponds. So he thought the pains were pulled muscles. Maybe he was drinking too much beer. He stayed in denial until... Read More »

Read More →

Derek Laurie was working as a tow truck driver, living in a suburb outside Rochester, New York, and supporting two small children. It was tough work. He climbed under wrecked vehicles, or swam into ponds. So he thought the pains were pulled muscles. Maybe he was drinking too much beer. He stayed in denial until… Read More »

[...]

Read More

IBM’s Watson is really good at creating cancer treatment plans

Jeopardy-winning Watson is getting better and better at designing cancer treatments. New data presented this week at the American Society of Clinical Oncology’s annual meeting show that IBM’s Watson for Oncology suggests cancer treatments that are often in-line with what physicians recommend. The company also announced that the cancer care product, designed to help physicians... Read More »

Read More →

Jeopardy-winning Watson is getting better and better at designing cancer treatments. New data presented this week at the American Society of Clinical Oncology’s annual meeting show that IBM’s Watson for Oncology suggests cancer treatments that are often in-line with what physicians recommend. The company also announced that the cancer care product, designed to help physicians… Read More »

[...]

Read More

Study finds first possible drug treatment for lymphedema

Collaboration between two Stanford labs has resulted in the discovery of a molecular cause for lymphedema and the first possible drug treatment for it. Tracey Campbell has lived for seven years with lymphedema, a chronic condition that causes unsightly swelling in her left leg. The disease, which stems from a damaged lymphatic system, can lead... Read More »

Read More →

Collaboration between two Stanford labs has resulted in the discovery of a molecular cause for lymphedema and the first possible drug treatment for it. Tracey Campbell has lived for seven years with lymphedema, a chronic condition that causes unsightly swelling in her left leg. The disease, which stems from a damaged lymphatic system, can lead… Read More »

[...]

Read More

FDA approves first new drug for ALS treatment in 22 years

The US Food and Drug Administration has approved the first new drug for the treatment of amyotrophic lateral sclerosis, or ALS, in more than two decades. The FDA announced Friday that Radicava, also known as edaravone, has been approved for use in the United States. The only other drug specifically for the treatment of ALS... Read More »

Read More →

The US Food and Drug Administration has approved the first new drug for the treatment of amyotrophic lateral sclerosis, or ALS, in more than two decades. The FDA announced Friday that Radicava, also known as edaravone, has been approved for use in the United States. The only other drug specifically for the treatment of ALS… Read More »

[...]

Read More

Page 1 of 2

Categories
Archives